| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 2.45% | 6.18% | 5.31% | -11.36% | — | — | — |
| Operating Margin | — | — | -2457.53% | -1325.24% | -1245.80% | -2224.39% | — | — | — |
| EBITDA Margin | — | — | -2196.68% | -1232.06% | -1168.45% | -2077.97% | — | — | — |
| Net Margin | — | — | -654.80% | -889.36% | -1758.64% | 539.78% | — | — | — |
| Current Ratio | 0.78 | 0.22 | 1.18 | 0.57 | 2.90 | 8.70 | 3.00 | 2.36 | 15.24 |
| Quick Ratio | 0.78 | 0.22 | 1.18 | 0.56 | 2.89 | 8.69 | 2.99 | 2.35 | 15.24 |
| Debt / Equity | 0.00 | 0.00 | 0.21 | 0.02 | 0.02 | 0.01 | 0.02 | 0.10 | 0.06 |
| ROE | -10.01% | -35.30% | -18.36% | -147.13% | -154.88% | 12.90% | -125.82% | -45.29% | -8.43% |
| ROA | -7.36% | -25.78% | -13.69% | -55.23% | -123.77% | 11.12% | -78.01% | -32.90% | -8.07% |
| Asset Turnover | 0.00 | 0.00 | 0.02 | 0.06 | 0.07 | 0.02 | — | — | — |
| Book Value / Share | — | — | 3.40 | 2.19 | 0.50 | 12.25 | 0.51 | 1.17 | — |
Aptorum Group Ltd. is a clinical stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs. It focuses primarily on oncology, including orphan oncology indications, infectious diseases, metabolic diseases, and women's health, through its Therapeutics segment, which develops drug molecules and diagnostic technologies. Key pipeline candidates include SACT-1, a repurposed drug in phase 1 trials for neuroblastoma and other cancers, and ALS-4, a small molecule in phase 1 for bacterial infections such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also advances preclinical programs like RPIDD for rapid pathogen diagnostics, SACT-COV19 for coronavirus, and others targeting bacterial infections and specific indications. Additionally, Aptorum Group Ltd. operates a Non-Therapeutics segment involving healthcare services and diagnostics. Founded in 2010 and headquartered in the United Kingdom, it plays a role in addressing critical gaps in biopharmaceutical innovation for challenging medical conditions.